Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL. 2017

Yuji Fujizuka, and Kazuto Ito, and Ryo Oki, and Rie Suzuki, and Yoshitaka Sekine, and Hidekazu Koike, and Hiroshi Matsui, and Yasuhiro Shibata, and Kazuhiro Suzuki
Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.

To investigate the predictive value of various molecular forms of prostate-specific antigen in men with baseline prostate-specific antigen <2.0 ng/mL. The case cohort comprised 150 men with a baseline prostate-specific antigen level <2.0 ng/mL, and who developed prostate cancer within 10 years. The control cohort was 300 baseline prostate-specific antigen- and age-adjusted men who did not develop prostate cancer. Serum prostate-specific antigen, free prostate-specific antigen, and [-2] proenzyme prostate-specific antigen were measured at baseline and last screening visit. The predictive impact of baseline prostate-specific antigen- and [-2] proenzyme prostate-specific antigen-related indices on developing prostate cancer was investigated. The predictive impact of those indices at last screening visit and velocities from baseline to final screening on tumor aggressiveness were also investigated. The baseline free to total prostate-specific antigen ratio was a significant predictor of prostate cancer development. The odds ratio was 6.08 in the lowest quintile baseline free to total prostate-specific antigen ratio subgroup. No serum indices at diagnosis were associated with tumor aggressiveness. The Prostate Health Index velocity and [-2] proenzyme prostate-specific antigen/free prostate-specific antigen velocity significantly increased in patients with higher risk D'Amico risk groups and higher Gleason scores. Free to total prostate-specific antigen ratio in men with low baseline prostate-specific antigen levels seems to predict the risk of developing prostate cancer, and it could be useful for a more effective individualized screening system. Longitudinal changes in [-2] proenzyme prostate-specific antigen-related indices seem to correlate with tumor aggressiveness, and they could be used as prognostic tool before treatment and during active surveillance.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Yuji Fujizuka, and Kazuto Ito, and Ryo Oki, and Rie Suzuki, and Yoshitaka Sekine, and Hidekazu Koike, and Hiroshi Matsui, and Yasuhiro Shibata, and Kazuhiro Suzuki
August 2017, International journal of urology : official journal of the Japanese Urological Association,
Yuji Fujizuka, and Kazuto Ito, and Ryo Oki, and Rie Suzuki, and Yoshitaka Sekine, and Hidekazu Koike, and Hiroshi Matsui, and Yasuhiro Shibata, and Kazuhiro Suzuki
February 2004, The Journal of urology,
Yuji Fujizuka, and Kazuto Ito, and Ryo Oki, and Rie Suzuki, and Yoshitaka Sekine, and Hidekazu Koike, and Hiroshi Matsui, and Yasuhiro Shibata, and Kazuhiro Suzuki
December 2007, The Journal of urology,
Yuji Fujizuka, and Kazuto Ito, and Ryo Oki, and Rie Suzuki, and Yoshitaka Sekine, and Hidekazu Koike, and Hiroshi Matsui, and Yasuhiro Shibata, and Kazuhiro Suzuki
April 2008, European urology,
Yuji Fujizuka, and Kazuto Ito, and Ryo Oki, and Rie Suzuki, and Yoshitaka Sekine, and Hidekazu Koike, and Hiroshi Matsui, and Yasuhiro Shibata, and Kazuhiro Suzuki
March 2017, International journal of urology : official journal of the Japanese Urological Association,
Yuji Fujizuka, and Kazuto Ito, and Ryo Oki, and Rie Suzuki, and Yoshitaka Sekine, and Hidekazu Koike, and Hiroshi Matsui, and Yasuhiro Shibata, and Kazuhiro Suzuki
April 2004, Urology,
Yuji Fujizuka, and Kazuto Ito, and Ryo Oki, and Rie Suzuki, and Yoshitaka Sekine, and Hidekazu Koike, and Hiroshi Matsui, and Yasuhiro Shibata, and Kazuhiro Suzuki
November 2011, The Journal of urology,
Yuji Fujizuka, and Kazuto Ito, and Ryo Oki, and Rie Suzuki, and Yoshitaka Sekine, and Hidekazu Koike, and Hiroshi Matsui, and Yasuhiro Shibata, and Kazuhiro Suzuki
June 2014, International journal of urology : official journal of the Japanese Urological Association,
Yuji Fujizuka, and Kazuto Ito, and Ryo Oki, and Rie Suzuki, and Yoshitaka Sekine, and Hidekazu Koike, and Hiroshi Matsui, and Yasuhiro Shibata, and Kazuhiro Suzuki
April 2016, BJU international,
Yuji Fujizuka, and Kazuto Ito, and Ryo Oki, and Rie Suzuki, and Yoshitaka Sekine, and Hidekazu Koike, and Hiroshi Matsui, and Yasuhiro Shibata, and Kazuhiro Suzuki
May 2000, The Journal of urology,
Copied contents to your clipboard!